{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:08:17Z","timestamp":1775664497035,"version":"3.50.1"},"reference-count":120,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2008,3,3]],"date-time":"2008-03-03T00:00:00Z","timestamp":1204502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The purpose of this work is to review the published strategies for the productionof prodrugs of amines. The review is divided in two main groups of approaches: those thatrely on enzymatic activation and those that take advantage of physiological chemicalconditions for release of the drugs. A compilation of the most important approaches ispresented in the form of a table, where the main advantages and disadvantages of eachstrategy are also referred.<\/jats:p>","DOI":"10.3390\/molecules13030519","type":"journal-article","created":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T12:45:09Z","timestamp":1222951509000},"page":"519-547","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Prodrugs for Amines"],"prefix":"10.3390","volume":"13","author":[{"given":"Ana L.","family":"Simpl\u00edcio","sequence":"first","affiliation":[{"name":"Instituto de Tecnologia Qu\u00edmica e Biol\u00f3gica, Universidade Nova de Lisboa, Av. da Rep\u00fablica \u2013 EAN, 2780-157 Oeiras, Portugal"},{"name":"IBET, Apartado 12, 2781-901 Oeiras, Portugal"}]},{"given":"John M.","family":"Clancy","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Trinity College, Dublin 2, Ireland"}]},{"given":"John F.","family":"Gilmer","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Trinity College, Dublin 2, Ireland"}]}],"member":"1968","published-online":{"date-parts":[[2008,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0378-5173(81)90096-X","article-title":"Prodrugs as drug delivery systems. XIX. Bioreversible derivatisation of aromatic amines by formation of N-Mannich bases with succinimide","volume":"8","author":"Bundgaard","year":"1981","journal-title":"Int. J. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0169-409X(92)90014-H","article-title":"Prodrugs as a means to improve the delivery of peptide drugs. 1","volume":"8","author":"Bundgaard","year":"1992","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/1381612805666230109214307","article-title":"Prodrug approaches to the improved delivery of peptide drugs","volume":"5","author":"Wang","year":"1999","journal-title":"Curr. Pharm. Des."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.theochem.2003.08.077","article-title":"Reaction profiling of the MAO-B catalyzed oxidative deamination of amines in Alzheimer's disease","volume":"666-667","author":"Gasparro","year":"2003","journal-title":"J. Mol. Struct.: THEOCHEM"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Testa, B., and Mayer, J.M. (2003). Hydrolysis in Drug and Prodrug metabolism, Chemistry, biochemistry and enzymology., Wiley-VCH. Chapter 4.","DOI":"10.1002\/9783906390444"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0361-9230(87)90164-X","article-title":"N,N-dipropargyl-2-phenylethylamine, a potential prodrug of 2-phenylethylamine: neurochemical and neuropharmacological studies in rat","volume":"19","author":"Rao","year":"1987","journal-title":"Brain Res. Bull."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00177747","article-title":"Pharmacokinetic and neurochemical studies on N-propargyl-2-phenylethylamine, a prodrug of 2-phenylethylamine","volume":"336","author":"Rao","year":"1987","journal-title":"N.-S. Arch. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1476-5381.1987.tb11318.x","article-title":"Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine","volume":"92","author":"Baker","year":"1987","journal-title":"Br. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0278-5846(87)90074-1","article-title":"N-(3-chloropropyl)phenylethylamine as a possible prodrug of beta-phenylethylamine: studies in the rat brain","volume":"11","author":"Rao","year":"1987","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_10","unstructured":"Bundgaard, H. (1985). Design of prodrugs, Elsevier. Chapter 1."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1527-3466.1992.tb00239.x","article-title":"An orally effective peripheral dopamine prodrug - Docarpamine TA-870","volume":"10","author":"Nishiyama","year":"1992","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/00005344-198900148-00005","article-title":"Cardiovascular and renal action of dopaminergic prodrugs","volume":"14","author":"Casagrande","year":"1989","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0169-409X(95)00108-J","article-title":"Prodrugs and targeted drug delivery","volume":"19","author":"Kearney","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1111\/j.1474-8673.1990.tb00235.x","article-title":"Five years experience with \u03b3-L-glutamyl-L-dopa- a relatively renally specific dopaminergic prodrug in man","volume":"10","author":"Lee","year":"1990","journal-title":"J. Auton. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1055\/s-2007-1013173","article-title":"Oral administration of the dopamine prodrug docarpamine shortens need for drip infusion of dopamine in patients with low cardiac output syndrome after cardiac surgery","volume":"47","author":"Matsubayashi","year":"1999","journal-title":"Thorac. Cardiovasc. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0024-3205(97)00706-6","article-title":"Effect of docarpamine, a novel orally active dopamine prodrug, on the formation of free and sulfoconjugated dopamine in patients who underwent cardiac surgery","volume":"61","author":"Tano","year":"1997","journal-title":"Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00005344-198908000-00001","article-title":"A novel orally active dopamine prodrug TA-870 II. Evidence that TA-870 is a dopamine prodrug","volume":"14","author":"Nishiyama","year":"1989","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0168-3659(96)01366-1","article-title":"New systems for the specific and sustained release of dopamine to the brain","volume":"42","author":"Carelli","year":"1996","journal-title":"J. Control. Release"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0090-9556(25)07567-1","article-title":"Pharmacokinetics of Dapsone and Amino Acid Prodrugs of Dapsone","volume":"22","author":"Pochopin","year":"1994","journal-title":"Drug Metab. Dispos."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0378-5173(95)00005-4","article-title":"Amino Acid Derivatives of Dapsone as Water-Soluble Prodrugs","volume":"121","author":"Pochopin","year":"1995","journal-title":"Int. J. Pharm."},{"key":"ref_21","first-page":"239","article-title":"Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles","volume":"1","author":"Bradshaw","year":"2002","journal-title":"Mol. Cancer. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0223-5234(99)80047-6","article-title":"Prodrugs of neuron-selective monoamine oxidase inhibitors: amino acid derivatives of 1-(4-aminophenyl)-2-aminopropanes","volume":"34","author":"Florvall","year":"1999","journal-title":"Eur. J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1124\/jpet.106.102830","article-title":"Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives","volume":"318","author":"Tsuda","year":"2006","journal-title":"Pharmaco.l Exp. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0378-5173(85)90011-0","article-title":"Allopurinol prodrugs. I. Synthesis, stability and physicochemical properties of various N1-acyl allopurinol derivatives","volume":"23","author":"Bundgaard","year":"1985","journal-title":"Int. J. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0024-3205(99)00466-X","article-title":"Kinetics of hydrolysis of acetyl, valeroyl and nicotinoyl acyl derivatives of stobadine","volume":"65","author":"Stankoviov","year":"1999","journal-title":"Life Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1021\/jm990533m","article-title":"A novel approach for a water-soluble long acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl]3-insulin","volume":"43","author":"Gershonov","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0006-291X(03)00715-0","article-title":"[2-sulfo)-9-fluorenylmethoxycarbonyl]3-exendin-4 a long acting glucose-lowering prodrug","volume":"305","author":"Shechter","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/S0968-0896(02)00097-4","article-title":"Synthesis and analysis of urea and carbamate prodrugs as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT)","volume":"10","author":"Jordan","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/AAC.47.6.2043-2046.2003","article-title":"Prodrugs of Cephalosporin RWJ-333441 (MC-04,546) with improved aqueous solubility","volume":"47","author":"Hecker","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0006-2952(95)02169-8","article-title":"Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6","volume":"51","author":"Yumibe","year":"1996","journal-title":"Biochem Pharmacol."},{"key":"ref_31","first-page":"1","article-title":"Desloratadine for the treatment of chronic urticaria","volume":"7","author":"Monroe","year":"2012","journal-title":"Skin Therapy Lett"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0968-0896(00)00087-0","article-title":"The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine","volume":"8","author":"Shimma","year":"2000","journal-title":"Bioorg Med Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cncr.21986","article-title":"Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers","volume":"107","author":"Ajani","year":"2006","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/jm7011479","article-title":"Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug","volume":"51","author":"Barthel","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0169-409X(95)00107-I","article-title":"Prodrugs for improved ocular drug delivery","volume":"19","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0378-5173(98)00043-X","article-title":"\/-Alkylcarbonyloxymethyl prodrugs of theophylline: topical delivery of theophylline","volume":"167","author":"Kerr","year":"1998","journal-title":"Int. J. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1021\/jm980539w","article-title":"Novel prodrug approach for tertiary amines: synthesis and preliminary evaluation of N-phosphonooxymethyl prodrugs","volume":"42","author":"Krise","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/js9803813","article-title":"A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of N-phosphonooxymethyl prodrugs","volume":"88","author":"Krise","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/js980382v","article-title":"A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs","volume":"88","author":"Krise","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0169-409X(95)00112-K","article-title":"A Case for Prodrugs: Fosphenytoin","volume":"19","author":"Stella","year":"1996","journal-title":"Adv. Drug Del. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0378-5173(87)90173-6","article-title":"N-(acyloxyalkoxycarbonyl) derivatives as potential prodrugs for amines. I. Kinetics and mechanism of degradation in aqueous solutions","volume":"40","author":"Gogate","year":"1987","journal-title":"Int. J. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0378-5173(87)90174-8","article-title":"N-(acyloxyalkoxycarbonyl) derivatives as potential prodrugs for amines. II. Esterase-catalysed release of parent amines from model prodrugs","volume":"40","author":"Gogate","year":"1987","journal-title":"Int. J. Pharm."},{"key":"ref_43","first-page":"2909","article-title":"Synthesis of (alkoxycarbonyloxy)methyl, (acyloxy)methyl and (oxodioxolenyl)methyl carbamates as bioreversible prodrug moieties for amines","volume":"22","author":"Li","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_44","unstructured":"Bundgaard, H. (1985). Design of prodrugs, Elsevier. Chapter 11."},{"key":"ref_45","unstructured":"Krogsgaard-Larsen, P., Liljefors, T., and Madsen, U. (2002). A textbook of drug design and discovery, Taylor and Francis. [3rd ed.]. Chapter 14."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1021\/jm00397a008","article-title":"(Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes","volume":"31","author":"Alexander","year":"1988","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/jm00105a013","article-title":"(Acyloxy)alkyl carbamate prodrugs of norfloxacin","volume":"34","author":"Alexander","year":"1991","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/jpet.104.067934","article-title":"XP13512 [(+\/-)-1-([(\u03b1-isobutanoyl-oxyethoxy)carbonyl]aminomethyl)-1-cyclohexane acetic acid], a Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters","volume":"311","author":"Cundy","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.104.067959","article-title":"XP13512 [(+\/-)-1-([(\u03b1-isobutanoyl-oxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a Novel Gabapentin Prodrug: II. Improved Oral Bioavailability, Dose Proportionality, and Colonic Absorption Compared with Gabapentin in Rats and Monkeys","volume":"311","author":"Cundy","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1021\/jm9506175","article-title":"Investigation of (oxodioxolenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral amines","volume":"39","author":"Alexander","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1023\/A:1018934200343","article-title":"Phosphoryloxymethyl carbamates and carbonates - novel water soluble prodrugs for amines and hindered alcohols","volume":"10","author":"Safadi","year":"1993","journal-title":"Pharm. Res."},{"key":"ref_52","first-page":"862","article-title":"The origin of 20th century discoveries transforming clinical gastroenterology","volume":"93","author":"Kirshner","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/j.1572-0241.2002.07092.x","article-title":"Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/jps.1126","article-title":"Colon-specific prodrug of 5-aminosalicylic acid: synthesis and in vitro\/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid","volume":"90","author":"Jung","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0360-3016(98)00302-2","article-title":"Bioreductive therapies: an overview of drugs and their mechanism of action","volume":"42","author":"Rauth","year":"1998","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0006-2952(02)00885-7","article-title":"Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release","volume":"63","author":"Everett","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1021\/jm00029a009","article-title":"Relationships between structure and kinetics of cyclization-activated aromatic mustards","volume":"37","author":"Atwell","year":"1994","journal-title":"J. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.bcp.2007.06.014","article-title":"Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia","volume":"74","author":"Guise","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1021\/jm960783s","article-title":"N-substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization","volume":"42","author":"Sykes","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1039\/p19960001205","article-title":"The 4-azidoberazyloxycarbonyl function: application as a novel protecting group and potential prodrug modification for amines","volume":"11","author":"Griffin","year":"1996","journal-title":"J. Chem. Soc. Perkin Trans. 1"},{"key":"ref_61","first-page":"S43","article-title":"Tertiary amines N-oxides as bioreductive drugs: DACA N-oxide, nitracarine N-oxide and AQ4N","volume":"27","author":"Wilson","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1126\/science.1166305","article-title":"Delivery of a quaternary pyridinium salt across the blood-brain barrier by its dihydropyridine derivative","volume":"190","author":"Bodor","year":"1975","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1126\/science.7313698","article-title":"Site-specific, sustained release of drugs to the brain","volume":"217","author":"Bodor","year":"1981","journal-title":"Science"},{"key":"ref_64","first-page":"93","article-title":"Chemical delivery systems for drugs containing an amino group: synthesis and properties of some pyridine derivatives of desipramine","volume":"5","author":"Pop","year":"1989","journal-title":"Drug. Des. Deliv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.6857264","article-title":"Redox delivery system for brain-specific, sustained release of dopamine","volume":"221","author":"Bodor","year":"1983","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jps.2600741002","article-title":"Direct evidence for brain-specific release of dopamine from a redox delivery system","volume":"10","author":"Simpkins","year":"1985","journal-title":"J. Pharm. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0169-409X(94)90038-8","article-title":"Improved brain delivery of antiviral agents through the use of redox targeting","volume":"14","author":"Brewster","year":"1994","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0378-5173(96)04554-1","article-title":"Redox targeting of LY231617, an antioxidant with potential use in the treatment of brain damage","volume":"140","author":"Pop","year":"1996","journal-title":"Int. J. Pharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/1098-1128(200009)20:5<367::AID-MED3>3.0.CO;2-P","article-title":"Targeting drug to the brain by redox chemical delivery systems","volume":"20","author":"Prokai","year":"2000","journal-title":"Med. Res. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0378-5173(94)00271-6","article-title":"Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds","volume":"116","author":"Ishikura","year":"1995","journal-title":"Int. J. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0968-0896(03)00038-5","article-title":"New carrier for specific delivery of drugs to the brain","volume":"11","author":"Sheha","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1021\/jm990166e","article-title":"Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds","volume":"42","author":"Greenwald","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0168-3659(01)00331-5","article-title":"PEG drugs: an overview","volume":"74","author":"Greenwald","year":"2001","journal-title":"J. Control. Release"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/jm990498j","article-title":"Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amine-containing compounds","volume":"43","author":"Greenwald","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/S0968-0896(03)00152-4","article-title":"Tripartate poly(ethylene glycol) prodrugs of the open lactone form of camptothecin","volume":"11","author":"Greenwald","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0169-409X(02)00180-1","article-title":"Effective drug delivery by PEGylated drug conjugates","volume":"55","author":"Greenwald","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Stella, V.J., Borchardt, R.T., Hageman, M.J., Oliyai, R., Maag, H., and Tilley, J.W. (2007). Prodrugs: Challenges and Rewards Part I, Springer. Chapter 2.3.1.","DOI":"10.1007\/978-0-387-49785-3"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/jm00085a012","article-title":"Low molecular weight proteins for renal drug targeting. Preparation of Drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates","volume":"35","author":"Franssen","year":"1992","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0168-3659(89)90021-7","article-title":"Physicochemical Propertiesband Antitumor Activities of Polymeric Prodrugs of Mitomycin C with Different Regeneration Rates","volume":"10","author":"Takakura","year":"1989","journal-title":"J. Control. Release"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejps.2004.11.006","article-title":"A new amino-masking group capable of pH-triggered amino-drug release","volume":"24","author":"Gilmer","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijpharm.2006.11.055","article-title":"\u03b2-Aminoketones as prodrugs with pH-controlled activation","volume":"336","author":"Gilmer","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1021\/jm00020a022","article-title":"Synthesis, X-ray christalography and pharmacokinetics of novel azomethine prodrugs of R-\u03b1-methylhistamine: highly potent and selective histamine H3-receptor agonists","volume":"38","author":"Krause","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2174\/0929867013372274","article-title":"Azomethine prodrugs of R-\u03b1-methylhistamine, a highly potent and selective histamine H3-receptor agonist","volume":"8","author":"Krause","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0968-0896(00)00237-6","article-title":"Enzyme-catalyzed prodrug approaches for the histamine H3-receptor agonist R-\u03b1-methylhistamine","volume":"9","author":"Stark","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jps.2600690112","article-title":"Prodrugs as drug delivery systems IV: N-mannich bases as potential novel prodrugs for amides, ureides, amines, and other NH-acidic compounds","volume":"69","author":"Bundgaard","year":"1980","journal-title":"J. Pharm. Sci."},{"key":"ref_86","unstructured":"Roche, E.B. (1987). Bioreversible Carriers in Drug Design, Pergamon Press."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0378-5173(80)90056-3","article-title":"Pro-drugs as drug delivery systems. XIII. Kinetics of decomposition of N-Mannich bases of salicylamide and assessment of their suitability as possible pro-drugs for amines","volume":"7","author":"Johansen","year":"1980","journal-title":"Int. J. Pharm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0378-5173(86)90195-X","article-title":"Prodrugs as drug delivery systems. 43. O-acyloxymethyl salicylamide N-Mannich bases as double prodrug forms for amines","volume":"29","author":"Bundgaard","year":"1986","journal-title":"Int. J. Pharm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0378-5173(81)90086-7","article-title":"Hydrolysis of N-Mannich bases and its consequences for the biological testing of such agents","volume":"9","author":"Bundgaard","year":"1981","journal-title":"Int. J. Pharm."},{"key":"ref_90","first-page":"111","article-title":"Pro-drugs as drug delivery systems. XXIV. N-Mannich bases as bioreversible lipophilic transport forms for ephedrine, phenethylamine and other amines","volume":"10","author":"Johansen","year":"1982","journal-title":"Arch. Pharm. Chemi. Sci. Ed."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Testa, B., and Mayer, J.M. (2003). Hydrolysis in Drug and Prodrug metabolism, Chemistry, biochemistry and enzymology, Wiley-VCH. Chapter 11.","DOI":"10.1002\/9783906390444"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1021\/jm000425w","article-title":"Synthesis and evaluation of oxodioxolenylmethyl carbamate prodrugs of pseudomycins","volume":"44","author":"Sun","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.bmcl.2007.11.029","article-title":"Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation","volume":"18","author":"Erez","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14787210.4.1.27","article-title":"Prulifloxacin: a new antibacterial fluoroquinolone","volume":"4","author":"Prats","year":"2006","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_95","first-page":"355","article-title":"Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent","volume":"26","author":"Tougou","year":"1998","journal-title":"Drug. Metab. Dispos."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/jps.2600601207","article-title":"Enamine prodrugs","volume":"60","author":"Caldwell","year":"1971","journal-title":"J. Pharm. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1248\/cpb.29.1986","article-title":"Biopharmaceutical study on the oral and rectal administration of enamine prodrugs of amino acid-like \u03b2-lactam antibiotics in rabbits","volume":"29","author":"Murakami","year":"1981","journal-title":"Chem. Pharm. Bull."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1039\/p29740000164","article-title":"A study of the rates of hydrolysis of certain enaminones","volume":"2","author":"Dixon","year":"1974","journal-title":"J. Chem. Soc. Perkin. Trans. 1I"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jps.2600790213","article-title":"Mechanism of hydrolysis and structure-stability relationship of enaminones as potential prodrugs of model primary amines","volume":"79","author":"Naringrekar","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0378-5173(86)90194-8","article-title":"Prodrugs as drug delivery systems. 42. 2-Hydroxymethylbenzamides and 2-acyloxymethylbenzamides as potential prodrug forms for amines","volume":"29","author":"Nielsen","year":"1986","journal-title":"Int. J. Pharm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/bioo.1996.0005","article-title":"Structural Analysis of a facile lactonization system facilitated by a \"trimethyl lock\"","volume":"24","author":"Wang","year":"1996","journal-title":"Bioorg. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1023\/A:1015890809507","article-title":"Amine prodrugs which utilize hydroxy amide lactonization. II. A potential esterase-sensitive amide prodrug","volume":"8","author":"Ameberry","year":"1991","journal-title":"Pharm. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1023\/A:1015885213625","article-title":"Amine prodrugs which utilize hydroxy amide lactonization. I. A potential redox-sensitive amide prodrug","volume":"8","author":"Amsberry","year":"1991","journal-title":"Pharm. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1021\/jo961477p","article-title":"Phosphate prodrugs for amines utilizing a fast intramolecular hydroxy amide lactonization","volume":"61","author":"Nicolaou","year":"1996","journal-title":"J. Org. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0960-894X(96)00147-3","article-title":"Chemical feasibility studies of a potential coumarin-based prodrug system","volume":"6","author":"Wang","year":"1996","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0968-0896(98)00014-5","article-title":"Coumarin-based prodrugs. Part 3: structural effects on the release kinetics of esterase-sensitive prodrugs for amines","volume":"6","author":"Wang","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0960-894X(99)00289-9","article-title":"Substituted coumarins as esterase-sensitive prodrug moieties with improved release rates","volume":"9","author":"Liao","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1248\/cpb.48.1138","article-title":"The effect of phenyl substituents on the release rates of esterase-sensitive coumarin-based prodrugs","volume":"48","author":"Liao","year":"2000","journal-title":"Chem. Pharm. Bul."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/1521-4184(200106)334:6<209::AID-ARDP209>3.0.CO;2-Y","article-title":"Coumarin derivatives as protease-sensitive prodrugs","volume":"334","author":"Achiles","year":"2001","journal-title":"Arch. Pharm."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0223-5234(94)90120-1","article-title":"Model for delivery of amines through incorporation into a tetrahydro-2H-1,3,5-thiadiazine-2-thione structure","volume":"29","year":"1994","journal-title":"Eur. J. Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0223-5234(96)80450-8","article-title":"New prodrug approach for amino acids and amino-acid-like drugs","volume":"31","year":"1996","journal-title":"Eur. J. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ardp.19973301103","article-title":"New carriers for representative peptides and peptide drugs","volume":"330","year":"1997","journal-title":"Arch. Pharm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1016\/S0960-894X(96)00526-4","article-title":"Coumarin-based prodrugs. 2. Synthesis and bioreversibility studies of an esterase sensitive cyclic prodrug of Dadle, an opioid peptide","volume":"6","author":"Wang","year":"1996","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1021\/js970069d","article-title":"Prodrug strategies based on intramolecular cyclization reactions","volume":"86","author":"Shan","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1012091014242","article-title":"Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropionic acid promoiety in a model hexapeptide","volume":"14","author":"Pauletti","year":"1997","journal-title":"Pharm. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1021\/jo961778z","article-title":"Synthesis of a novel esterase-sensitive cyclic prodrug system for peptides that utilises a \"trimethyl lock\"-facilitated lactonization reaction","volume":"62","author":"Wang","year":"1997","journal-title":"J. Org. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0378-5173(82)90096-5","article-title":"Pro-drugs as drug delivery systems XX. Oxazolidines as potential pro-drug types for \u03b2-aminoalcohols, aldehydes and ketones","volume":"10","author":"Bundgaard","year":"1982","journal-title":"Int. J. Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0378-5173(91)90349-S","article-title":"Prodrugs of peptides 15. 4-imidazolidinone prodrug derivatives of enkephalins to prevent amino-catalyzed peptidase metabolism in plasma and absortive mucosae","volume":"76","author":"Rasmussen","year":"1991","journal-title":"Int. J. Pharm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0928-0987(03)00198-2","article-title":"Kinetics of degradation of 4-imidazolidinone prodrug types obtained from reacting prilocaine with formaldehyde and acetaldehyde","volume":"20","author":"Larsen","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0928-0987(98)00044-X","article-title":"N-terminal 4-imidazolidinone prodrugs of Leu-enkephalin: synthesis, chemical and enzymatic stability studies","volume":"7","author":"Bak","year":"1999","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/13\/3\/519\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:20:29Z","timestamp":1760221229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/13\/3\/519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,3]]},"references-count":120,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,3]]}},"alternative-id":["13030519"],"URL":"https:\/\/doi.org\/10.3390\/molecules13030519","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,3]]}}}